Cogent Biosciences Inc Aktie News

WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences, Inc. (NASDAQ:COGT ) Citi's Biopharma Back to School Conference September 3, 2025 9:00 AM EDT Company Participants Andrew Robbins - President, CEO & Director Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Good morning. Thank you for coming to the 2025 Citi Biopharma Conference in Boston.

WALTHAM, Mass. and BOULDER, Colo.

Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025 $453 million in pro-forma cash sufficient to fund operations through anticipated launch and into 2027; i...

Insider buying has been slow this month, as buy windows close ahead of the new earnings-reporting season.

WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to t...

I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib in NonAdvSM by end of 2025, with additional pivotal data readouts expected in AdvSM and GIST in 2nd half 2025. Cogent is well-funded, raising $200M recently and maintaining a cash runway into late ...

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The a...